NCT00370721Unknown3 期
Intravitreal Bevacizumab for Management of Active Progressive Proliferative Diabetic Retinopathy (PDR)
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 试验地点
- 1
- 主要终点
- Regression of diabetic retinopathy
研究概览
简要总结
To evaluate the effect of intravitreal bevacizumab on the course of diabetic retinopathy in cases with the signs of active progressive PDR
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Cases of active progressive PDR with history of scatter laser photocoagulation
排除标准
- •history of vitrectomy
研究组 & 干预措施
I
Experimental
干预措施: bevacizumab (Drug)
结局指标
主要结局
Regression of diabetic retinopathy
visual acuity
次要结局
- neovascularization
- fibrous proliferation
- traction retinal detachment
- vitreous hemorrhage
- pan retinal photocoagulation
研究者
研究点 (1)
Loading locations...
相似试验
已完成
4 期
Intravitreal Bevacizumab for Proliferative Diabetic RetinopathyVitreous HemorrhageProliferative Diabetic RetinopathyNCT01724385Khon Kaen University18
Unknown
不适用
Efficacy and Safety of Intravitreal Bevacizumab for Threshold ROP.Stage 2+ or Stage 3+ Retinopathy of Prematurity in Zone I or Zone II.NCT01707745Sivakami A Pai50
已完成
不适用
Intravitreal Bevacizumab and Triamcinolone in Diabetic Macular EdemaDiabetic Macular EdemaNCT01342159Hallym University Medical Center80
Unknown
2 期
Intravitreal Bevacizumab for Diabetic Macular EdemaMacular EdemaDiabetic RetinopathyNCT00703235Isfahan Ophthalmology Research Center
撤回
3 期
Use of Intravitreal Bevacizumab in Patients With Diffuse Diabetic Macular EdemaDiabetes Mellitus Type 2Diabetic Macular EdemaNCT00417716Asociación para Evitar la Ceguera en México